Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction

Stephen Boyle, Cameron Wellard, Elizabeth M. Moore, Hilary Blacklock, Simon J. Harrison, Phoebe Joy Ho, Jay Hocking, Zoe K. McQuilten, Hang Quach, Ruth Spearing, Erica M. Wood, Andrew Spencer, Peter Mollee, Myeloma and Related Diseases Registry investigators

Research output: Contribution to journalLetterOtherpeer-review

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)497-499
Number of pages3
JournalEuropean Journal of Haematology
Issue number4
Publication statusPublished - Oct 2021

Cite this